Express antibodies with enhanced antibody-dependent cellular cytotoxicity (ADCC) with proven POTELLIGENT®CHOK1SV®technology
Get support in the production of antibodies with enhanced antibody-dependent cellular cytotoxicity (ADCC), helping you to improve the efficacy of your cytotoxic therapeutic candidates. The POTELLIGENT® CHOK1SV® host cell line and recombinant cell lines derived from POTELLIGENT® CHOK1SV® exhibit good growth characteristics.
Antibodies produced by this cell line:
- Can exert potent cytotoxic effects even when their target antigen density is low
- Retain all the other desirable features of antibodies such as Protein A binding
Take advantage of our established CHOK1SV® cell line lineage
In the growing field of therapeutic antibodies, drug developers are continually searching for new strategies to improve efficacy. Optimization of antibody molecules by Fc engineering is a major opportunity here. Potency can be increased by enhancing antibody-dependent cellular cytotoxicity (ADCC) – 100% fucose-free antibodies in glycan moieties show much higher ADCC activity than normally fucosylated antibodies.
Through our partnership with BioWa, we can help you take advantage of this strategy. By fully removing fucose content, BioWa’s POTELLIGENT® Technology can increase the potency and efficacy of your antibody drugs. The POTELLIGENT® CHOK1SV® cell line technology enables the rapid expression of highly productive and stable recombinant cell lines.